LYDIA
LYDIA: Impact Of Liraglutide On Cardiac Function And Structure In Young Adults With Type 2 Diabetes: An Open-Label, Randomised Active-Comparator Trial
Study Title
The traditional demographic profile of Type 2 diabetes (T2DM) has dramatically altered over the last couple of decades; the sharp rise in levels of obesity and sedentary lifestyles witnessed in younger age groups in developed countries has resulted in up to a 10-fold increase in the prevalence of T2DM in younger adults and youth. T2DM in the young is associated with a particularly deleterious phenotype, including a high risk of early cardiovascular disease and impaired cardiac function.
Background
This novel trial aims to assess whether Liraglutide,a GLP-1 analogue, leads to improved left ventricular diastolic function in younger adults with T2DM compared to the clinical relevant active comparator Sitagliptin, a DPP-4 inhibitor.
Study Aims
A Prospective, Open-label, Randomised, Blinded End-point (PROBE) active-comparator trial will be employed with 90 individuals randomised (1:1) to receive a maintenance dose of 1.8 mg/daily Liraglutide or 100mg/daily Sitagliptin. The primary outcome will be peak end diastolic strain rate, measured by gold-standard tagged cardiac MRI at baseline and 26-weeks. Secondary outcomes include a host of biochemical, anthropometric and lifestyle variables.
Study Summary
Closed
Study progress
Data Protection
The study is match funded by Novo Nordisk as part of an investigator initiated grant.